PORCINE SECRETIN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for PORCINE SECRETIN (PORCINE SECRETIN).
Stimulates exocrine pancreatic secretion by acting on secretin receptors on pancreatic ductal cells, increasing bicarbonate and water secretion. Also stimulates bile and gastric acid secretion.
| Metabolism | Metabolized by enzymatic degradation; half-life approximately 2 minutes. |
| Excretion | Primarily renal, with over 90% of the administered dose eliminated via glomerular filtration and tubular reabsorption; fecal and biliary excretion are negligible. |
| Half-life | The terminal elimination half-life is approximately 4-6 minutes, reflecting rapid degradation by plasma proteases; this short half-life limits its systemic duration of action and necessitates continuous infusion for sustained secretory testing. |
| Protein binding | Less than 10% bound to plasma proteins, primarily albumin; negligible binding precludes significant protein-based interactions. |
| Volume of Distribution | Approximately 0.1-0.2 L/kg, indicating limited extravascular distribution and confinement mainly to the plasma compartment; consistent with a high-molecular-weight peptide. |
| Bioavailability | Intravenous: 100%; oral bioavailability is negligible due to proteolytic degradation in the gastrointestinal tract, and no other routes (e.g., subcutaneous, intramuscular) are approved or reliably absorbed. |
| Onset of Action | Intravenous: within 1 minute; onset is nearly immediate with peak effect on pancreatic secretion occurring 2-5 minutes after bolus injection. No other route is clinically used. |
| Duration of Action | Intravenous: 10-20 minutes; the brief duration is due to rapid clearance, requiring repeated boluses or continuous infusion for prolonged diagnostic testing of pancreatic exocrine function. |
0.2 mcg/kg intravenous bolus over 1 minute, maximum 20 mcg.
| Dosage form | INJECTABLE |
| Renal impairment | No specific GFR-based dose adjustments established. Use with caution in severe renal impairment (eGFR <30 mL/min/1.73m²) due to limited data. |
| Liver impairment | No specific Child-Pugh based adjustments. In severe hepatic impairment (Child-Pugh class C), consider risk of adverse effects; monitor closely. |
| Pediatric use | Safety and efficacy not established; no approved dosing guidelines. |
| Geriatric use | No specific dose adjustment; increase monitoring for adverse effects due to potential age-related decreased renal/hepatic function. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for PORCINE SECRETIN (PORCINE SECRETIN).
| Breastfeeding | Excretion in human milk unknown. Caution advised; M/P ratio not determined. Consider benefit versus risk. |
| Teratogenic Risk | No adequate and well-controlled studies in pregnant women. Animal reproduction studies have not been conducted. Unknown risk to fetus; use only if clearly needed. First trimester: theoretical risk of altered gastrointestinal hormone effects. Second trimester: no specific data. Third trimester: potential indirect effects due to maternal response. |
| Fetal Monitoring |
■ FDA Black Box Warning
None.
| Serious Effects |
["Hypersensitivity to porcine secretin or any component","Acute pancreatitis (relative)"]
| Precautions | ["May cause allergic reactions including anaphylaxis","Use with caution in patients with acute pancreatitis or biliary obstruction","Avoid extravasation during injection"] |
Loading safety data…
| Monitor maternal vital signs and gastrointestinal response during administration. Fetal heart rate monitoring not specifically required unless used in procedures affecting pregnancy. |
| Fertility Effects | No data on fertility impairment. Animal studies not performed. Unknown effect on human reproductive function. |